Phase II trial of trimelamol in refractory ovarian cancer.

Trimelamol is an analogue of hexamethymelamine which exhibited activity against refractory ovarian cancer in phase I clinical trial. The dose limiting toxicity was leukopenia. In a phase II study, 42 patients with recurrent, or platinum-complex resistant, advanced ovarian cancer were treated using t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Judson, I. R., Calvert, A. H., Gore, M. E., Balmanno, K., Gumbrell, L. A., Perren, T., Wiltshaw, E.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group 1991
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC1971798/
https://ncbi.nlm.nih.gov/pubmed/1997112
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia